November 2023 in “Bioorganic Chemistry” This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.
December 2022 in “CRC Press eBooks” This research outlines that antiandrogens have mechanisms involving competitive inhibition of androgen binding and enzyme inhibition, with contraindications during pregnancy due to potential fetal risks.
December 2024 in “Frontiers in Endocrinology” This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.